<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Piano Mortari E</submitter><funding>Italian Ministry of Health</funding><pagination>2541</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8533837</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(10)</volume><pubmed_abstract>Specific memory B cells and antibodies are a reliable read-out of vaccine efficacy. We analysed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase, thus predicting a sustained protection from COVID-19. We show that although mucosal IgA is not induced by the vaccination, memory B cells migrate in response to inflammation and secrete IgA at mucosal sites. We show that the first vaccine dose may lead to an insufficient number of highly specific memory B cells and low concentration of serum antibodies, thus leaving vaccinees without the immune robustness needed t</pubmed_abstract><journal>Cells</journal><pubmed_title>Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA.</pubmed_title><pmcid>PMC8533837</pmcid><funding_grant_id>RF2013-02358960 grant</funding_grant_id><funding_grant_id>COVID-2020-12371817 grant</funding_grant_id><pubmed_authors>Terreri S</pubmed_authors><pubmed_authors>Ruggiero A</pubmed_authors><pubmed_authors>Fernandez Salinas A</pubmed_authors><pubmed_authors>Agosta M</pubmed_authors><pubmed_authors>Roscilli G</pubmed_authors><pubmed_authors>Magnavita N</pubmed_authors><pubmed_authors>Russo N</pubmed_authors><pubmed_authors>Locatelli F</pubmed_authors><pubmed_authors>Meschi S</pubmed_authors><pubmed_authors>Cotugno N</pubmed_authors><pubmed_authors>Zaffina S</pubmed_authors><pubmed_authors>Alteri C</pubmed_authors><pubmed_authors>Piano Mortari E</pubmed_authors><pubmed_authors>Linardos G</pubmed_authors><pubmed_authors>Piccioni L</pubmed_authors><pubmed_authors>Brugaletta R</pubmed_authors><pubmed_authors>Carsetti R</pubmed_authors><pubmed_authors>Russo C</pubmed_authors><pubmed_authors>Salvatori G</pubmed_authors><pubmed_authors>Giorgio D</pubmed_authors><pubmed_authors>Coltella L</pubmed_authors><pubmed_authors>Santoro A</pubmed_authors><pubmed_authors>Pavoni E</pubmed_authors><pubmed_authors>Corsetti T</pubmed_authors><pubmed_authors>Agrati C</pubmed_authors><pubmed_authors>Vinci MR</pubmed_authors><pubmed_authors>Castilletti C</pubmed_authors><pubmed_authors>Ranno S</pubmed_authors><pubmed_authors>Camisa V</pubmed_authors><pubmed_authors>Colagrossi L</pubmed_authors><pubmed_authors>Ciofi Degli Atti ML</pubmed_authors><pubmed_authors>Perno CF</pubmed_authors><pubmed_authors>Amodio D</pubmed_authors><pubmed_authors>Albano C</pubmed_authors><pubmed_authors>Romania P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA.</name><description>Specific memory B cells and antibodies are a reliable read-out of vaccine efficacy. We analysed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase, thus predicting a sustained protection from COVID-19. We show that although mucosal IgA is not induced by the vaccination, memory B cells migrate in response to inflammation and secrete IgA at mucosal sites. We show that the first vaccine dose may lead to an insufficient number of highly specific memory B cells and low concentration of serum antibodies, thus leaving vaccinees without the immune robustness needed t</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2025-04-20T02:03:24.318Z</modification><creation>2025-04-20T02:03:24.318Z</creation></dates><accession>S-EPMC8533837</accession><cross_references><pubmed>34685521</pubmed><doi>10.3390/cells10102541</doi></cross_references></HashMap>